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Abstract
Aims/hypothesis Diabetes diagnosed at <6 months of age is usually monogenic. However, 10–15% of affected infants do not
have a pathogenic variant in one of the 26 known neonatal diabetes genes. We characterised infants diagnosed at <6 months of
age without a pathogenic variant to assess whether polygenic type 1 diabetes could arise at early ages.
Methods We studied 166 infants diagnosed with type 1 diabetes at <6 months of age in whom pathogenic variants in all 26 known
genes had been excluded and compared themwith infants with monogenic neonatal diabetes (n = 164) or children with type 1 diabetes
diagnosed at 6–24 months of age (n = 152). We assessed the type 1 diabetes genetic risk score (T1D-GRS), islet autoantibodies, C-
peptide and clinical features.
Results We found an excess of infants with high T1D-GRS: 38% (63/166) had a T1D-GRS >95th centile of healthy individuals,
whereas 5% (8/166) would be expected if all were monogenic (p < 0.0001). Individuals with a high T1D-GRS had a similar rate
of autoantibody positivity to that seen in individuals with type 1 diabetes diagnosed at 6–24months of age (41% vs 58%, p = 0.2),
and had markedly reduced C-peptide levels (median <3 pmol/l within 1 year of diagnosis), reflecting rapid loss of insulin
secretion. These individuals also had reduced birthweights (median z score −0.89), which were lowest in those diagnosed with
type 1 diabetes at <3 months of age (median z score −1.98).
Conclusions/interpretation We provide strong evidence that type 1 diabetes can present before the age of 6 months based on
individuals with this extremely early-onset diabetes subtype having the classic features of childhood type 1 diabetes: high genetic
risk, autoimmunity and rapid beta cell loss. The early-onset association with reduced birthweight raises the possibility that for
some individuals there was reduced insulin secretion in utero. Comprehensive genetic testing for all neonatal diabetes genes
remains essential for all individuals diagnosed with diabetes at <6 months of age.








T1D-GRS Type 1 diabetes genetic risk score
ZnT8A Zinc transporter 8 autoantibody
Introduction
Diabetes that presents in the first 6 months of life (neonatal
diabetes) has been thought to be exclusively caused by a path-
ogenic variant in a single gene; nearly 90% of individuals
have one of 26 known causes depending on cohort definition,
highlighting the need for comprehensive genetic testing [1–6].
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The remaining ~10–15% may have a causative pathogenic
variant in a gene or non-coding region that has not yet been
identified. Another possibility is that they have polygenic type
1 diabetes and represent the extreme tail of the distribution of
presenting age of type 1 diabetes [7].
Type 1 diabetes accounts for the vast majority of diabetes in
childhood [8] and is a complex autoimmune condition caused by a
combination of genetic risk and environmental factors. Established
features of type 1 diabetes include positivity for islet-specific auto-
antibodies (GAD autoantibody [GADA], insulinoma antigen-2
autoantibody [IA2A] and zinc transporter 8 autoantibody
[ZnT8A]) [9], and progression to low or absent C-peptide due to
beta cell destruction and resultant insulin deficiency [10, 11].
There are rare examples of autoimmune diseases, including auto-
immune diabetes, presenting before the age of 6 months but these
are caused either by highly penetrant pathogenic variants in
immune genes such as FOXP3, STAT3 and LRBA [2, 3, 12] or,
as for neonatal lupus, by passive transfer of pathogenic maternal
antibodies [13]. To our knowledge, no polygenic autoimmune
diseases (including type 1 diabetes) have been described and
characterised in individuals below the age of 6 months.
We recently performed an analysis of type 1 diabetes
genetic risk in people referred to our centre for genetic testing
for monogenic diabetes [7]. We showed that a type 1 diabetes
genetic risk score (T1D-GRS), which expresses genetic risk as
a continuum, could be used to discriminate type 1 diabetes
from monogenic diabetes including neonatal diabetes
(NDM). Furthermore, we studied 48 infants diagnosed at
age <6 months without a genetic pathogenic variant and
identified an excess of infants with high polygenic type 1
diabetes risk, raising the hypothesis that there are children
with polygenic type 1 diabetes diagnosed under the age of
6 months.
In this study, we aimed to characterise infants diagnosed
with diabetes at <6 months of age without monogenic NDM
who had high type 1 diabetes genetic risk, in order to confirm
whether they have features consistent with type 1 diabetes and
further define their phenotype.
Methods
Cohorts
We studied two groups of infants with diabetes onset at
<6 months of age, and a group of children diagnosed with
type 1 diabetes at older ages. The first group of infants had
no detectable pathogenic variants in the 26 genetic loci known
to cause NDM. The second group of infants had monogenic
NDM with a detectable pathogenic variant.
Individuals with diabetes of unknown genetic aetiology diag-
nosed before 6 months of age We studied 166/1438 (12%)
individuals referred to our laboratory for genetic testing for
permanent NDM between 2000 and 2019 in whom comprehen-
sive targeted next-generation sequencing had excluded a patho-
genic variant in the 26 known genes. Clinical information was
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provided by the referring physician via a referral form available
at www.diabetesgenes.org.
Individuals with type 1 diabetesWe compared genetic risk for
type 1 diabetes in our cohorts with a reference cohort of 1962
individuals with type 1 diabetes (from the Wellcome Trust
Case Control Consortium [14]). We additionally compared
their islet autoantibodies and C-peptide levels with those of
152 individuals diagnosed between 6 months and 2 years of
age who were originally referred for monogenic diabetes test-
ing but subsequently diagnosed with type 1 diabetes. We
measured C-peptide (n = 64) and autoantibody levels (n =
88) in all available samples. Monogenic diabetes was exclud-
ed by comprehensive genetic testing in all individuals diag-
nosed at 6–9 months of age [15].
Individuals with monogenic diabetes diagnosed before
6 months of age We used a comparator group of individuals
with monogenic permanent NDM (n = 164) caused by either
heterozygous pathogenic ABCC8 (n = 25), KCNJ11 (n = 72)
or INS (n = 67) variants. We measured islet autoantibodies
(n = 93) and serum C-peptide (n = 111), depending on sample
availability.
Genetic testing
Testing of the known genes All individuals diagnosed in the
first 9 months of life were tested by rapid Sanger sequencing
ofABCC8,KCNJ11 and INS and, if no pathogenic variant was
identified, via targeted next-generation sequencing (tNGS) of
all 26 known genetic causes of permanent NDM (electronic
supplementary material [ESM] Table 1). Historic samples
were tested for new genetic causes as they were discovered.
This assay can detect single nucleotide variants, insertion–
deletions, copy number variants and structural variation [16].
T1D-GRSWe generated the T1D-GRS as previously described
[17]. Briefly, we genotyped single SNPs tagging the top 30
risk alleles for type 1 diabetes (ESM Table 2) and summed
their log10-transformed ORs before dividing by the total
number of alleles to obtain a numeric score. High/low T1D-
GRS was defined as an individual’s score being above or
below 0.280, the 95th centile of 4862 control individuals with-
out type 1 diabetes [14].
Biomarker measurement EDTA–blood samples were collect-
ed to extract DNA for genetic testing. All samples were spun
at 1300 g for 8 min and, where it could be separated, plasma
was stored at −80°C.
Antibody measurement Antibody testing was undertaken by
radiolabel assays at the Pacific Northwest Diabetes Research
Institute, USA. Cut-offs for positivity were defined as the 99th
percentile of >200 individuals from a control healthy popula-
tion [18]. The laboratory participates in the Diabetes
Autoantibody Standardization Program (DASP)/Islet
Autoantibody Standardization Program (IASP) proficiency
testing and each separate autoantibody assay is Clinical
Laboratory Improvement Amendments (CLIA) certified
(CLIA no. 50D0982418).
C-peptide measurement C-peptide was measured in EDTA–
plasma from samples of blood couriered or posted to the
laboratory primarily for genetic testing. These samples were
usually postprandial but the relationship to the eating of meals
was not stipulated. We have previously demonstrated the
stability of C-peptide in EDTA–plasma [19]. C-peptide was
analysed using a direct electrochemiluminescence immunoas-
say (Roche Diagnostics, Mannheim, Germany) as previously
described [20]. The limit of detection of the assay is 3 pmol/l
and for statistical analysis we coded values below the limit of
detection as 2.9 pmol/l.
Ethics approval
All study participants gave informed consent or assent was
obtained where children were too young and parental consent
was provided, in accordance with the declaration of Helsinki.
This study was approved by the Genetic Beta Cell Research
Bank, Exeter, UK. Ethical approval was provided by the
North Wales Research Ethics Committee, UK (IRAS project
ID 231760).
Statistical analysis
The Mann–Whitney U and Kruskal–Wallis tests were used to
compare continuous variables and the Fisher’s exact test was
used to compare categorical variables. Statistical analysis was
undertaken in Stata14 (StataCorp, College Station, TX, USA).
Birthweight z scores (adjusted for sex and gestational age)
were calculated based onWHO international reference ranges
[21].We performed sensitivity analyses stratified by ethnicity.
A p value of <0.05 was used to define statistical significance.
Results
High T1D-GRS identifies probable type 1 diabetes
diagnosed before the age of 6 months
We identified an excess of infants with high T1D-GRS in the
group diagnosed before the age of 6 months without a mono-
genic diagnosis (Fig. 1). Of the 166 infants, 63 (38%) had a
T1D-GRS above the 95th centile of the healthy control children
without type 1 diabetes (>0.280; Table 1). Only 8 (5%)would be
expected to have scores this high if these individuals all had a
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novel undiscovered monogenic aetiology (p < 0.0001), as indi-
viduals with monogenic diabetes have the same distribution of
T1D-GRS as seen in individuals without type 1 diabetes (i.e. 5%
above the 95th centile). The excess of individuals with high
T1D-GRS suggests that this subset of individuals has polygenic
type 1 diabetes. This also suggests that type 1 diabetes accounts
for at least 4% (excess no. of individuals [observed−expected]/
total no. of individuals; [63–8]/1438) of our international cohort
of 1438 individuals from 108 countries who were diagnosed
with diabetes before the age of 6 months.
Performing the analysis only on white Europeans (n = 45)
identified a similar proportion of individuals with a T1D-GRS
above the 95th centile of healthy control individuals (18/45
[40%] vs 63/166 [38%], p = 0.9). This suggests that the results
are not due to the population structure of our cohort. We
therefore defined the 63 children with scores above the 95th
centile as having likely type 1 diabetes and hypothesised that
they would have features of polygenic type 1 diabetes.
Islet autoantibody prevalence in children diagnosed
before the age of 6 months with a high T1D-GRS
Infants diagnosed with diabetes before the age of 6 months
with a high T1D-GRS and no known cause had islet-specific
autoantibody prevalence similar to that found in children with
type 1 diabetes diagnosed between 6 months and 2 years of
age. Serum was available for autoantibody measurement from
22/63 of the children with a high T1D-GRS and no known
cause. Of these 22 children, nine (41%) were positive for at
least one of GADA, IA2A or ZnT8A (Fig. 2). This was similar
to the proportion of autoantibody-positive individuals with
type 1 diabetes diagnosed between 6 months and 2 years of
age (9/22 vs 51/88, p = 0.2) (Fig. 2) who had similar duration
of diabetes to those with diabetes diagnosed at <6 months of
age with a high T1D-GRS (median duration 3.0 vs 4.0 years,
p = 0.3) (Table 1). The proportion of infants who were diag-
nosed with diabetes at <6 months of age and who had a high
T1D-GRS that were positive for an antibody was higher than
that of infants with confirmed non-autoimmune monogenic
diabetes (9/22 vs 7/93, p = 0.0004). Of the infants who were
diagnosed with diabetes at <6 months of age and who had a
high T1D-GRS, 2/22 (10%) were positive for two antibodies
and one was positive for all three antibodies. The characteris-
tics of those where antibody testing was possible vs not possi-
ble were similar (ESM Table 3).
As all infants were insulin treated at referral, we were
unable to discern insulin autoantibody (IAA) status pertaining
to endogenous insulin from IAAs to exogenous insulin. That
notwithstanding, we found a higher proportion of infants posi-
tive for IAAs in those with likely type 1 diabetes diagnosed at
<6 months of age than in those with monogenic NDM (18/22
vs 38/98, p = 0.0003) or those with a low T1D-GRS (18/22 vs
12/28, p = 0.008) (ESM Fig. 1). This was particularly the case
if the duration of insulin treatment was ≤3 months (4/8 vs
6/75, p = 0.006) (ESMFig. 2). However, as duration of insulin
treatment increased, the proportion in both groups was similar,
presumably due to accumulation of antibodies to exogenous
insulin with prolonged exposure.
Evidence for severe insulin deficiency
We found that the high T1D-GRS group had low C-peptide
levels at the time of referral for genetic analysis for all dura-
tions of diabetes. Within 12 months of diabetes diagnosis
(median duration 1 month [IQR 0.3–3], n = 7), the children
with diabetes diagnosed before the age of 6 months and a high
T1D-GRS had lower C-peptide levels than the infants with
monogenic diabetes (median <3 vs 64 pmol/l, p = 0.003) and
those with diabetes diagnosed before the age of 6 months and
a low T1D-GRS (<3 vs 117 pmol/l, p = 0.004) (Fig. 3). The
high T1D-GRS group diagnosed before the age of 6 months
had similar C-peptide levels to the group diagnosed with type
1 diabetes between the ages of 6 months and 2 years (<3 vs
24.5 pmol/l, p = 0.22). The same pattern was observed when
including all diabetes durations (ranging from 2 days to
20 years) (ESM Fig. 3).
In infants with diabetes diagnosed before the age of
6 months, all three biomarkers of type 1 diabetes (high T1D-
GRS, positive for an islet autoantibody, low/absent C-peptide)
were present in six from 19 tested for all three.
Low birthweight is a characteristic of very-early-onset
diabetes
We found that the infants whowere diagnosed with diabetes at
<6 months of age with high T1D-GRS had reduced
birthweight compared with the WHO international reference
















Fig. 1 Distribution of T1D-GRS in control population (individuals with-
out diabetes) (black line, n = 2938) and individuals with diabetes diag-
nosed at <6 months of age without a known genetic cause (grey bars, n =
166). Hatched bars represent the enrichment of individuals with high
T1D-GRS, above the control population distribution. The dashed line
represents the 95th centile of the control population (0.280)
Diabetologia
[21]. Interestingly, we found earlier age at diagnosis of diabe-
tes was associated with lower birthweight (r2 = 0.18, p =
0.001) (Fig. 4), with individuals diagnosed in the first
3 months of life having markedly reduced birthweight (z
score: −1.98 [IQR −2.33, −1.23], n = 17). These individ-
uals with the earliest onset (<3 months) had similar T1D-
GRS (0.299 vs 0.296, p = 0.3) and C-peptide values (2.9
vs 2.9, p = 0.4) to those diagnosed at 3–6 months of age
(ESM Table 4). In those with the earliest onset, 3/7 were
positive for IAA; however, none were positive for GADA,
IA2A or ZnT8A, possibly due to the extremely young age
of onset in these individuals. Children diagnosed with type
1 diabetes between the ages of 6 months and 2 years had
birthweights similar to those of the normal population (z
score −0.25 [IQR −0.89, 0.59], n = 125, Table 1), suggest-
ing that reduced birthweight is not a feature in later-onset
type 1 diabetes. Infants with monogenic NDM also had
reduced birthweights (median −1.39), as genetic beta cell
Table 1 Clinical and demographic features of individuals with type 1 diabetes diagnosed in the first 6 months of life
Characteristic Monogenic NDM
(n = 164)
Diabetes diagnosed before 6 months of age Type 1 diabetes
diagnosed at
6–24 months of
age (n = 152)
Low T1D-GRS (n = 103) High T1D-GRS (n = 63)
T1D-GRS 0.233 (0.217, 0.245)
(n = 115)
0.241 (0.219, 0.252) 0.298 (0.292, 0.304) 0.294 (0.261, 0.310)
(n = 102)
Age at diagnosis (weeks) 9 (4, 15) 4 (1, 12) 16 (6, 21) 48 (39, 56)








Female sex, n (%) 86 (52) 40 (39) 27 (43) 60 (40)
Related parents, n/n (%)b 20/157 (13) 24/100 (24) 15/63 (24) 12/89 (13)
First-degree relative with
type 1 diabetes, n/n (%)
1/152 (1) 1/97 (1) 10/61 (16) 11/88 (13)
Mother with type 1 diabetes, n/n (%) 0/152 (0) 0/97 (0) 1/61 (2) 2/88 (2)
Father with type 1 diabetes, n/n (%) 1/152 (1) 0/97 (0) 4/61 (7) 3/88 (3)
Sibling with type 1 diabetes, n/n (%) 0/152 (0) 1/97 (1) 6/61 (10) 6/88 (7)
Insulin treated from diagnosis, n/n (%) 164/164 (100) 103/103 (100) 63/63 (100) 152/152 (100)








HbA1c, mmol/mol 69 (56, 101) (n = 107) 64 (44, 74) (n = 49) 65 (58, 78) (n = 54) 76 (62, 87) (n = 59)
HbA1c, % 8.5 (7.3, 11.4) 8.0 (6.2, 8.9) 8.1 (7.5, 9.3) 9.1 (7.8, 10.1)








Duration of diabetes at sampling 5.5 m (1.0 m, 8.2 y) 1.5 m (0.7 m, 1.7 y) 7.9 m (2.2 m, 5.3 y) 2.9 y (1.5 m, 15.1 y)
Syndromic presentation, n (%) 5 (3) 28 (27) 6 (9) 1 (1)
Additional autoimmune
condition, n (%)
1 (1) 7 (7) 3 (4) 15 (10)
Autoantibody positive, n/n (%)
GADA/IA2A/ZnT8A 7/93 (8) 4/33 (12) 9/22 (41) 51/88 (58)
GADA 2/93 (2) 4/33 (12) 6/22 (27) 39/88 (44)
IA2A 4/93 (4) 0/33 (0) 4/22 (16) 13/88 (15)
ZnT8A 1/93 (1) 0/33 (0) 3/22 (14) 7/88 (8)
Age at antibody measurement 26 w (13 w, 5.8 y) 20 w (5 w, 9 y) 3.7 y (4.6 m, 8.5 y) 4 y (1 y, 17 y)
Duration of diabetes at
antibody measurement
11 w (3 w, 6 y) 6 w (3 w, 9 y) 3.0 y (2.3 m, 7.5 y) 4.0 y (6 w, 14 y)
C-peptide, pmol/l
Duration of diabetes <12 months 64 (13, 138) (n = 61) 117 (16, 362) (n = 15) <3 (<3, 10) (n = 7) 24.5 (<3, 67) (n = 26)
Duration of diabetes >12 months 8.5 (<3, 40) (n = 50) <3 (<3, 63) (n = 10) <3 (<3, <3) (n = 12) <3 (<3, <3) (n = 38)
All data are median (IQR) unless otherwise specified
a Based on WHO international reference range, adjusted for sex and gestation period
bDefined as parents being second cousins or closer relatives
m, months; w, weeks; y, years
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defects reduce insulin secretion and therefore insulin-
mediated growth in utero.
There was also a relationship between lower birthweight and
earlier diagnosis for individuals diagnosed before the age of
6 months with low GRS (ESM Fig. 4). This likely reflects
reduced insulin secretion in utero as seen in known forms of
monogenic NDM.
Clinical and demographic features of type 1 diabetes
diagnosed at <6 months
We analysed the clinical and demographic information for
individuals with type 1 diabetes diagnosed at <6 months of
age defined by high T1D-GRS (Table 1). The median age of
diabetes diagnosis of these individuals was 16 weeks (range
1–25 weeks; IQR 6, 21 weeks). The youngest individual with
a positive islet autoantibody was diagnosed at 16 weeks. The
median duration of diabetes at sampling was 7.9 months (IQR
2.2 months, 5.3 years). All individuals were treated with insu-
lin from diagnosis and the median insulin dose at referral was
0.81 U/kg daily (IQR 0.50, 1.00). The median HbA1c of these
individuals was 65 mmol/mol (IQR 58, 78) (8.1% [IQR 7.5,
9.3]) and median blood glucose at diagnosis was 30 mmol/l
(IQR 23, 38.1).
The number of individuals who had a first-degree
relative (parent or sibling) with type 1 diabetes was
10/61 (16%), in keeping with rates reported in other
studies of family history in type 1 diabetes [22]. The
number of individuals who were the result of a consan-
guineous union (parents being second cousins or more
closely related) was 15 (24%), similar to the rate in our
entire cohort of individuals diagnosed at <6 months of
age (332/1438 [23%]) and therefore likely reflecting the

























Fig. 3 Serum C-peptide (pmol/l) in infants with diabetes of a known
monogenic cause (n = 63, control group), diabetes with an unknown
cause diagnosed before the age of 6 months with a low T1D-GRS (n =
15) and with a high T1D-GRS (n = 7), and type 1 diabetes diagnosed
between the ages of 6 months and 2 years (n = 28). C-peptide is plotted
on a log scale. The dashed horizontal line represents 200 pmol/l, with C-
peptide values below this considered low. All samples were taken within
1 year of the diagnosis of diabetes. The central line within the box repre-
sents the median and the upper and lower limits of the box represent the
IQR. The whiskers are the most extreme values within 1.5× the IQR from






































Fig. 2 Proportion of infants positive for anti-islet autoantibodies in those
with diabetes of a knownmonogenic cause (n = 93, control group), diabe-
tes with an unknown cause diagnosed before the age of 6 months with a
low T1D-GRS (n = 33) and with a high T1D-GRS (n = 22), and type 1
diabetes diagnosed between the ages of 6 months and 2 years (n = 88).
Dark blue bars, positive for at least one of GADA, IA2A or ZnT8A;
purple bars, GADA positive; red bars, IA2A positive; light blue bars,
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Fig. 4 Scatter plot of adjusted birthweight z score and age at diagnosis of
diabetes in weeks in children with high T1D-GRS (n = 48). The fitted line
is the predicted linear regression (r2 = 0.18, p = 0.001) with grey shading
representing the 95% CI. Black circles, islet autoantibody positive; white




Wehave shown that type 1 diabetes can present before the age of
6months using the combinedmeasurement of a T1D-GRS, three
islet autoantibodies and C-peptide. The combination of high
levels of islet autoantibody positivity, reduced C-peptide and
high type 1 diabetes genetic susceptibility makes a strong case
that these individuals have polygenic type 1 diabetes. To our
knowledge, type 1 diabetes is the first example of a polygenic
autoimmune disease presenting before the age of 6 months. We
identified individuals who were diagnosed in the first weeks of
life and had low birthweight, suggesting reduced insulin secre-
tion in utero and therefore reduced insulin-mediated growth. Our
results therefore increase focus on how the nascent immune
systemmight develop islet autoimmunity, and the circumstances
that make type 1 diabetes possible at such young ages.
We identified individuals with type 1 diabetes below the age
of 6 months. There was a marked excess of individuals with a
T1D-GRS >95th centile of the normal population (63/166 vs
8/166 expected) in our cohort of 166 individuals diagnosed at
<6months of agewho did not have a pathogenic variant in any of
the 26 known genetic causes of NDM. By taking only the excess
numbers, we conservatively estimate that the proportion of type 1
diabetes in our international cohort of 1438 cases of diabetes
diagnosed before age 6 months would be 4%.
There are very few studies assessing type 1 diabetes under the
age of 6 months. Huopio et al studied diabetes diagnosed at
<12 months of age in Finland and showed that type 1 diabetes
was more likely in individuals diagnosed at >6 months of age
and monogenic diabetes was more likely in those diagnosed at
<6 months of age [23]. However, some of the reported cases of
diabetes diagnosed at <6 months of age were likely to be type 1
diabetes, as evidenced by 5/30 individuals not having a patho-
genic variant in any of the genes tested and being islet autoanti-
body positive. Our study in 2016 analysed type 1 diabetes genet-
ic risk and highlighted potential type 1 diabetes in individuals
diagnosed before the age of 6months, althoughwe did not assess
established biomarkers (islet autoantibodies and C-peptide) [7].
Another potential source of information is longitudinal birth stud-
ies but considering the incidence of all diabetes under the age of
6 months (1/20,000 to 1/500,000 live births) [24–28], unsurpris-
ingly none of these have identified a case of type 1 diabetes
diagnosed this early.
Autoantibodies to islet antigens are a hallmark feature of older
children with type 1 diabetes, with >90% of individuals being
positive for GADA, IA2A and/or ZnT8A autoantibodies [9]. We
observed at least one islet autoantibody in 41% of those diag-
nosedwith diabetes at <6months of agewith high T1D-GRS and
in 58% of those diagnosed between the ages of 6 months and
2 years. The lower number of antibody-positive individuals diag-
nosed at <6 months of age with high T1D-GRS, when compared
with individualswith older-onset type 1 diabetes,may be partially
explained by IAA positivity. Eighty-two per cent of individuals
diagnosed before the age of 6 months with high T1D-GRS were
IAApositive comparedwith 39%of thosewith non-autoimmune
monogenicNDM.However, we cannot rule out that this is due to
immunity to exogenous insulin. We were not able to exclude
maternal transfer of antibodies, although none of the individuals
who were antibody positive had a mother with type 1 diabetes,
and the cut-offs used to define positivity (99th centile of healthy
individuals) mean that we would only expect 1% of the non-
diabetic population to be positive for any antibody. A low
number of individuals with monogenic NDM were positive for
a single antibody, in keeping with the false-positive rate expected
by the threshold used (p= 0.3 for all antibodies, p> 0.4 for each
individual antibody). The T1D-GRS was similar in the individ-
uals with monogenic diabetes cases who were positive vs nega-
tive for an antibody (median 0.236 vs 0.233, p= 0.7). No indi-
viduals with monogenic NDM were positive for >1 antibody.
A characteristic of type 1 diabetes diagnosed at <6 months of
age was rapid beta cell destruction. We found that 14/19 (74%)
of individuals diagnosed before the age of 6 months with high
T1D-GRS had undetectable C-peptide (<3 pmol/l) when
measured at follow-up. Only three of the seven individuals stud-
ied within a year of diagnosis (median 1 month) had detectable
C-peptide and levels were all below 39 pmol/l. This is in keeping
with previous data indicating that, in type 1 diabetes, earlier age
of diagnosis is associated with rapid progression to severe insulin
deficiency: children diagnosed before the age of 18 years have
faster progression than those diagnosed as adults [29, 30] and
children diagnosed before the age of 5 years show faster progres-
sion than those diagnosed after the age of 5 years [31].
Additionally, longitudinal studies have shown that children at
risk of type 1 diabetes who develop islet autoantibodies early
show faster progression to overt disease, supporting a more rapid
onset and shorter presymptomatic phase in younger children
[32]. The faster progression to insulin deficiency may represent
similar rates of decline in beta cell mass but lower initial beta cell
mass in those diagnosed at a young age [33, 34]. This may be
particularly relevant to our cohort given that the expansion of
beta cell mass in humans is limited to very early life [35]. Our
study is cross sectional and longitudinal studies are needed to
properly define C-peptide decline in type 1 diabetes diagnosed
at <6 months of age.
An interesting and unique finding in our study is the low
birthweight in our cohort of individuals diagnosed at
<6 months of age with high T1D-GRS. This was most marked
in those diagnosed in the first 3 months of life, with a reduc-
tion in corrected birthweight of approximately 900 g (SD
−1.98). This raises the possibility that there is a common
explanation for the low birthweight and extremely early onset
of diabetes in these individuals. This is compatible with the
severe insulin deficiency that results in a presentation of
diabetes soon after birth existing in utero, resulting in reduced
insulin-mediated growth and hence lower birthweight. Insulin
is a potent fetal growth factor and absent fetal insulin secretion in
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individuals with pancreatic agenesis results in greatly reduced
birthweight (approximately −1400 g, SD 3) [36, 37]. In
immunodysregulation polyendocrinopathy enteropathy X-
linked (IPEX) syndrome, a monogenic autoimmune disease
caused by hemizygous pathogenic FOXP3 variants [12], islet
autoimmunity has been observed in pancreases from affected
miscarried fetuses showing that it is possible to develop islet
autoimmunity in utero [38]. Other possible explanations include
maternal factors that could cause low birthweight such as
unrecognised infection/illness or nutritional deficits during preg-
nancy [39]. Previous studies in type 1 diabetes after 6 months
have shown amodest increase (HR 1.13) in overall risk of type 1
diabetes in large for gestational age babies [40, 41]. Individuals
with a low T1D-GRS also showed reduced birthweights (z score
−1.23), which may reflect as-yet unknown monogenic causes of
NDM,where there is often a defect resulting in reduced or absent
insulin secretion during fetal development. We did not see an
association with low birthweight in children with type 1 diabetes
diagnosed between the ages of 6 months and 2 years, suggesting
that this is a specific feature of very-young-onset diabetes.
This is the first characterisation of polygenic autoimmunity
diagnosed in the first 6 months of life. The neonatal immune
system is immature and biased towards tolerance at birth.
However, it undergoes rapid change in the first months of life
to prepare infants for diverse immune challenges [42].
Primary defects in the immune system, particularly in regula-
tory T cell function, are known to cause autoimmunity includ-
ing autoimmune diabetes in neonates [43]. This suggests that a
major failure of early immune tolerance mechanisms may
underlie type 1 diabetes diagnosed before the age of 6 months.
This failure may be triggered by environmental factors such as
specific viral infection during pregnancy or in the first few
months of life [44]. Characterisation of microbiome, virome
and immune phenotype in individuals diagnosed at <6months
of age with high T1D-GRS could provide mechanistic
insights into how the nascent immune system can develop a
specific targeted attack against beta cells.
Our study further demonstrates the utility of polygenic risk
scores for disease stratification and studying rare subtypes.
Unlike biomarkers, genetic information does not change over
time and is easily tested using a small volume of blood or
saliva. Furthermore, DNA should be readily available from
all individuals diagnosed with diabetes before the age of
6 months as they are commonly referred for genetic testing
of NDM genes [1].
While we have demonstrated that type 1 diabetes can present
under the age of 6 months, comprehensive genetic testing is still
essential for all infants diagnosed with diabetes below the age of
6 months as 85–90% have a known monogenic cause and in
~50% of those a genetic diagnosis can optimise therapy [45].
This testing is available free for any individual diagnosed at
<6 months of age, whatever their current age (www.
diabetesgenes.org). Monogenic diabetes is identified in
approximately 5% of individuals diagnosed at 6–9 months of
age and in this age group polygenic type 1 diabetes is more likely
[15]. In this age group it is therefore important to assess all the
clinical information available as genetic testing may be indicated
in some individuals. Furthermore, as syndromic presentation is
common in monogenic disease, individuals diagnosed with
diabetes at >6 months of age with additional features (e.g.
exocrine insufficiency, autoimmune disorders, liver disease,
neurological features) or with other factors making a monogenic
causemore likely (e.g. consanguinity or a family history suggest-
ing mendelian inheritance) should be considered for genetic test-
ing. It is important to note that these guidelines are pragmatic and
not perfect; there are rare cases of monogenic diabetes diagnosed
in the first years of life that remain difficult to identify using cut-
off points and rely on the observation of astute clinicians. The
T1D-GRS is a useful tool for the proportion of individuals in
whom a genetic mutation has been ruled out by comprehensive
testing. As such, it may be time and cost effective to include it on
NDM genetic testing panels so that the data are available if no
monogenic cause is identified.When a genetic cause is ruled out,
islet autoantibody status may be useful in combination with the
T1D-GRS. However, islet autoantibody positivity does not
preclude amonogenic cause as individualswithmonogenic auto-
immunity (e.g. IPEX syndrome) commonly have islet autoanti-
bodies and may present at >6 months of age. It is rare but possi-
ble for islet autoantibodies to appear after diagnosis in type 1
diabetes [46], therefore longitudinal study of islet autoantibodies
in this very young group is warranted as it is possible that anti-
bodies could appear later as the immune system matures.
Our study has some limitations. We were unable to
unequivocally diagnose all infants as having type 1 diabetes
at <6 months of age as a small proportion of individuals with
monogenic diabetes have a high T1D-GRS (~5%) due to the
distribution of risk alleles in the population. However, all
individuals were screened and were negative for pathogenic
variants in the 26 known genetic causes. A major limitation is
that we were unable to measure autoantibodies or C-peptide in
all individuals as we did not have sufficient samples for the
analysis. Many samples for autoantibody measurement were
collected years after diagnosis of diabetes and we are therefore
unable to rule out loss or gain of islet autoantibodies during
the intervening time. Our sample collection for C-peptide
measurement was random, rather than being under controlled
conditions. However, we found that individuals with type 1
diabetes (diagnosed at <6 months of age or between 6 months
and 2 years of age) had lower C-peptide levels than those with
monogenic NDM, supporting the validity of the results.
In conclusion, we have shown that type 1 diabetes can present
before the age of 6 months and is characterised by rapid beta cell
loss and islet autoimmunity. This extreme form of autoimmune
diabetes is the first polygenic autoimmune disease demonstrated
to present before the age of 6 months, challenging current under-
standing of the early immune system.
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